| Literature DB >> 18342798 |
Andreas Sewing1, Toby Winchester, Pauline Carnell, David Hampton, Wilma Keighley.
Abstract
Bringing drugs to the market remains a costly and, until now, often unpredictable challenge. Although understanding the underlying science is key to further progress, our imperfect knowledge of disease and complex biological systems leaves excellence in execution as the most tangible lever to sustain our serendipitous approach to drug discovery. The problems encountered in pharmaceutical R&D are not unique, but to learn from other industries it is important to recognise similarity, rather than differences, and to advance industrialisation of R&D beyond technology and automation. Tools like Lean and Six Sigma, already applied to increase business excellence across diverse organisations, can equally be introduced to pharmaceutical R&D and offer the potential to transform operations without large-scale investment.Entities:
Mesh:
Year: 2008 PMID: 18342798 DOI: 10.1016/j.drudis.2007.11.011
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851